PTGX (Protagonist Therapeutics) FFO


PTGX Protagonist Therapeutics Inc PTGX
51 GF Score
Price $122.58
GF Value $58.69
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Protagonist Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

PTGX
51GF Score
Protagonist Therapeutics Inc PTGX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Protagonist Therapeutics (PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of $122.58 is trading 108.9% above its estimated GF Value™ of $58.69. GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.

Key valuation signals for PTGX:

  • FFO:
  • GF Value™: $58.69 vs. price of $122.58 (108.9% above fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protagonist Therapeutics Business Description

Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
51GF Score

Get the complete analysis for PTGX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$122.58
Price
$58.69
GF Value